SHARE:  

Best of ASCO 2024


NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)


Date/Time: June 4, 2024; 9:45am-12:45pm CDT


Location: Hall D1 & Livestream


Session:

Primary Track: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary


Presenter: Karyn A. Goodman, MD

Oral Presentations

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)


Date/Time: May 31, 2024; 2:45-5:45pm CDT


Location: Arie Crown Theater & Livestream


Session:

Lung Cancer - Non Small Cell Metastatic


Presenter: Puneeth Iyengar, MD, PhD

Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724


Date/Time: June 2, 2024; 8:00-11:00am CDT


Location: Hall D2 & Livestream


Session:

Gynecologic Cancer


Presenter: Anuja Jhingran, MD

Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003


Date/Time: June 3, 2024; 4:30-6:00pm CDT


Location: S100a & Livestream


Session:

The Art and Science of Hope


Presenter: Benjamin W. Corn, MD

Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations


Date/Time: June 3, 2024; 8:00-11:00am CDT


Location: S100bc & Livestream


Session:

Central Nervous System Tumors


Presenter: Priscilla Kaliopi Brastianos, MD

ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer


Date/Time: June 3, 2024; 3:00-6:00pm CDT


Location: Hall B1 & Livestream


Session:

Breast Cancer - Local/Regional/Adjuvant


Presenter: Tarah Jean Ballinger, MD

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)


Date/Time: June 3, 2024; 3:00-6:00pm CDT


Location: Hall B1 & Livestream


Session:

Breast Cancer - Local/Regional/Adjuvant


Presenter: Kevin Kalinsky, MD, MS

Full List of NRG ASCO 2024 Presentations

A full listing of all NRG ASCO 2024 presentations, including oral, rapid oral, and poster presentations can be found on the NRG website at the link below.

NRG Presentation Flyer
Twitter      Facebook      Instagram      LinkedIn      YouTube